Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant Depression

NCT05624268 is registered in ClinicalTrials.gov with COMPASS Pathways as lead sponsor.

NCT NCT05624268
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05624268 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant Depression
Lead sponsor
COMPASS Pathways
Phase
Phase 3
Overall status
Completed
Start date
January 24, 2023
Completion date
April 15, 2026
Enrollment
258 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

treatment resistant depression